Small Molecules
31 October 2018
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen30 October 2018
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting30 October 2018
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP29 October 2018
Esperion Announces Positive Top-Line Results from Final Pivotal Phase 3 Study of Bempedoic Acid29 October 2018
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH28 October 2018
Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders25 October 2018
Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia25 October 2018
Cortexyme Announces Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer’s Patients25 October 2018
FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease24 October 2018
Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis23 October 2018
Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injectionNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports